NeoGenomics, Inc. NEO
15.41 USD -0.61 (-3.81%)
Regular-session close
15.41 0.00 0.00%
After hours · Nov 16, 4:26 PM ET
15.36 Day range 15.78
7.07 52-week range 20.15
- YTD
- +31.04%
- 1 year
- +49.03%
News
businesswire.com Better Adds $43.7 Million in Volume Across Two Purchase-Focused Teams in California and the Mid-Atlantic Through NEO Home Loans Channel NEW YORK--(BUSINESS WIRE)---- $BETR #BETR--Better Home & Finance Holding Company (NASDAQ: BETR) today announced that two established mortgage teams have joined NEO Home Loans, powered by Better. The…
globenewswire.com FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track DENVER, Nov. 11, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews ) — NeOnc Technologies Holdings (NASDAQ: NTHI) secured a Type B End-of-Phase meeting, scheduled for early January 2027, with the U.S. Food…
globenewswire.com NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100 CALABASAS, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for…
defenseworld.net Neo Performance Materials Q3 Earnings Call Highlights Neo Performance Materials (TSE: NEO) raised its full-year 2026 earnings outlook after reporting a sharp increase in third-quarter revenue and adjusted earnings, as demand and pricing strengthened…benzinga.com TD Cowen Maintains Buy on NeoGenomics, Raises Price Target to $23 TD Cowen analyst Dan Brennan maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $19 to $23.
benzinga.com NeoGenomics Q3 2026 Earnings Call Transcript NeoGenomics (NASDAQ:NEO) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…benzinga.com NeoGenomics Raises FY2026 Sales Guidance from $802.000M-$806.000M to $807.000M-$809.000M vs $805.827M Est NeoGenomics (NASDAQ:NEO) raises FY2026 sales outlook from $802.000 million-$806.000 million to $807.000 million-$809.000 million vs $805.827 million estimate.
benzinga.com NeoGenomics Q3 Adj. EPS $0.07 Beats $0.05 Estimate, Sales $209.254M Beat $207.328M Estimate NeoGenomics (NASDAQ:NEO) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.05 by 40 percent. This is a 133.33 percent increase over earnings of $0.03 per…
